Andreas Weihofen

4.1k total citations · 1 hit paper
31 papers, 3.1k citations indexed

About

Andreas Weihofen is a scholar working on Neurology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Andreas Weihofen has authored 31 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Neurology, 14 papers in Molecular Biology and 11 papers in Cellular and Molecular Neuroscience. Recurrent topics in Andreas Weihofen's work include Parkinson's Disease Mechanisms and Treatments (19 papers), Nuclear Receptors and Signaling (9 papers) and Alzheimer's disease research and treatments (5 papers). Andreas Weihofen is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (19 papers), Nuclear Receptors and Signaling (9 papers) and Alzheimer's disease research and treatments (5 papers). Andreas Weihofen collaborates with scholars based in United States, Switzerland and Germany. Andreas Weihofen's co-authors include Dennis J. Selkoe, Bruno Martoglio, Marius K. Lemberg, Beth L. Ostaszewski, Matthew J. LaVoie, Michael G. Schlossmacher, Keith Ashman, Cathrin Meißner, Holger Lorenz and Mark Cookson and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Andreas Weihofen

30 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dopamine covalently modifies and functionally inactivates parkin

2005 580 citations Matthew J. LaVoie, Beth L. Ostaszewski et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andreas Weihofen United States	20	1.5k	1.1k	685	667	580	31	3.1k
Judith Blanz Germany	20	1.2k 0.8×	609 0.5×	1.1k 1.6×	436 0.7×	1.1k 1.9×	26	3.2k
Alan S. Jonason United States	12	1.5k 1.0×	477 0.4×	236 0.3×	438 0.7×	605 1.0×	15	3.3k
Christian Bernreuther Germany	34	1.4k 1.0×	249 0.2×	525 0.8×	654 1.0×	248 0.4×	75	3.3k
Haibin Xia China	19	2.4k 1.6×	266 0.2×	417 0.6×	457 0.7×	188 0.3×	80	3.5k
Frederik Vilhardt Denmark	24	1.3k 0.9×	255 0.2×	448 0.7×	338 0.5×	260 0.4×	39	2.7k
Marianna Sikorska Canada	39	2.9k 1.9×	204 0.2×	330 0.5×	504 0.8×	458 0.8×	78	4.3k
Christian Behrends Germany	36	3.3k 2.2×	549 0.5×	705 1.0×	602 0.9×	3.1k 5.3×	85	6.1k
Dulce Papy-García France	30	1.4k 1.0×	395 0.4×	761 1.1×	346 0.5×	96 0.2×	83	2.9k
Jette Wypych United States	29	2.1k 1.4×	1.3k 1.1×	1.0k 1.5×	538 0.8×	67 0.1×	65	4.7k
Hyangshuk Rhim South Korea	25	984 0.7×	430 0.4×	322 0.5×	267 0.4×	142 0.2×	82	1.7k

Countries citing papers authored by Andreas Weihofen

Since Specialization

Citations

This map shows the geographic impact of Andreas Weihofen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Weihofen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Weihofen more than expected).

Fields of papers citing papers by Andreas Weihofen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Weihofen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Weihofen. The network helps show where Andreas Weihofen may publish in the future.

Co-authorship network of co-authors of Andreas Weihofen

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Weihofen. A scholar is included among the top collaborators of Andreas Weihofen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Weihofen. Andreas Weihofen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hering, Heike, Thierry Bussière, Chia‐Chen Liu, et al.. (2025). A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies. Molecular Neurodegeneration. 20(1). 88–88.

Liu, Yuting, Minhua Yang, Kyle Fraser, et al.. (2024). Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples. Journal of Pharmacology and Experimental Therapeutics. 392(1). 100003–100003. 3 indexed citations

Abraham, Neeta A., Nadine F. Joseph, Sarah Geisler, et al.. (2024). Dose-dependent reduction of somatic expansions but not Htt aggregates by di-valent siRNA-mediated silencing of MSH3 in HdhQ111 mice. Scientific Reports. 14(1). 2061–2061. 5 indexed citations

Nicholatos, Justin W., David Tran, Yuting Liu, Warren D. Hirst, & Andreas Weihofen. (2022). Lysophosphatidylcholine acyltransferase 1 promotes pathology and toxicity in two distinct cell-based alpha-synuclein models. Neuroscience Letters. 772. 136491–136491. 6 indexed citations

Zhao, Hien, Neena S. John, Vedad Delic, et al.. (2021). LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model. Molecular Therapy — Nucleic Acids. 24. 1051–1053. 2 indexed citations

Shlevkov, Evgeny, Paramasivam Murugan, Eric Stefan, et al.. (2021). Discovery of small-molecule positive allosteric modulators of Parkin E3 ligase. iScience. 25(1). 103650–103650. 19 indexed citations

Nicholatos, Justin W., David Tran, Lori Hrdlicka, et al.. (2021). SCD Inhibition Protects from α-Synuclein-Induced Neurotoxicity But Is Toxic to Early Neuron Cultures. eNeuro. 8(4). ENEURO.0166–21.2021. 12 indexed citations

Bantle, Collin M., Warren D. Hirst, Andreas Weihofen, & Evgeny Shlevkov. (2021). Mitochondrial Dysfunction in Astrocytes: A Role in Parkinson’s Disease?. Frontiers in Cell and Developmental Biology. 8. 608026–608026. 62 indexed citations

Bryś, Mirosław, Laura Fanning, Serena Hung, et al.. (2019). Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054. Movement Disorders. 34(8). 1154–1163. 139 indexed citations

10.

Bryś, Mirosław, Aaron Ellenbogen, Laura Fanning, et al.. (2018). Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease (S26.001). Neurology. 90(15_supplement). 17 indexed citations

11.

Zhao, Hien, Vedad Delic, Aneeza Kim, et al.. (2017). LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model. Molecular Therapy — Nucleic Acids. 8. 508–519. 155 indexed citations

12.

Zhao, Hien, Tracy Cole, Andreas Weihofen, Eric E. Swayze, & Holly Kordasiewicz. (2016). Antisense oligonucleotides to LRRK2 ameliorate alpha-synuclein pathology and behavioral deficit induced by pre-formed alpha-synuclein fibrils (I1.007). Neurology. 86(16_supplement). 1 indexed citations

13.

Meißner, Cathrin, Holger Lorenz, Andreas Weihofen, Dennis J. Selkoe, & Marius K. Lemberg. (2011). The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. Journal of Neurochemistry. 117(5). 856–867. 304 indexed citations

14.

Berger, Anne, et al.. (2009). Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Human Molecular Genetics. 18(22). 4317–4328. 69 indexed citations

15.

Weihofen, Andreas, Beth L. Ostaszewski, Yasufumi Minami, & Dennis J. Selkoe. (2007). Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. Human Molecular Genetics. 17(4). 602–616. 122 indexed citations

16.

Friedmann, Elena, Marius K. Lemberg, Andreas Weihofen, et al.. (2004). Consensus Analysis of Signal Peptide Peptidase and Homologous Human Aspartic Proteases Reveals Opposite Topology of Catalytic Domains Compared with Presenilins. Journal of Biological Chemistry. 279(49). 50790–50798. 79 indexed citations

17.

Weihofen, Andreas, Marius K. Lemberg, Elena Friedmann, et al.. (2003). Targeting Presenilin-type Aspartic Protease Signal Peptide Peptidase with γ-Secretase Inhibitors. Journal of Biological Chemistry. 278(19). 16528–16533. 109 indexed citations

18.

Viollier, Patrick H., Andreas Weihofen, Marc Folcher, & Charles J. Thompson. (2002). Post-transcriptional Regulation of the Streptomyces coelicolor Stress Responsive Sigma Factor, SigH, Involves Translational Control, Proteolytic Processing, and an Anti-sigma Factor Homolog. Journal of Molecular Biology. 325(4). 637–649. 35 indexed citations

19.

Lemberg, Marius K., et al.. (2001). Intramembrane Proteolysis of Signal Peptides: An Essential Step in the Generation of HLA-E Epitopes. The Journal of Immunology. 167(11). 6441–6446. 154 indexed citations

20.

Weihofen, Andreas, Marius K. Lemberg, Hidde L. Ploegh, Matthew Bogyo, & Bruno Martoglio. (2000). Release of Signal Peptide Fragments into the Cytosol Requires Cleavage in the Transmembrane Region by a Protease Activity That Is Specifically Blocked by a Novel Cysteine Protease Inhibitor. Journal of Biological Chemistry. 275(40). 30951–30956. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact